ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.

Ignace  Vergote

Consulting or Advisory Role - Agenus; Akeso Biopharma; AstraZeneca; Bristol Myers Squibb; Deciphera; Eisai; Elevar Therapeutics; Exelixis; Genmab; GlaxoSmithKline; Immunogen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Mersana; MSD; Novartis; Novocure; Oncoinvent; OncXerna Therapeutics; Regeneron; Roche; Sanofi; Seagen; Sotio; Verastem; Zentalis

Research Funding - Amgen (Inst); Oncoinvent (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Genmab; Karyopharm Therapeutics; Novocure

Mansoor R.  Mirza

Leadership - Karyopharm Therapeutics; Sera Prognostics

Stock and Other Ownership Interests  - Karyopharm Therapeutics; Sera Prognostics

Honoraria - Allarity Therapeutics; AstraZeneca; Geneos; Genmab/Seattle Genetics; GlaxoSmithKline; Merck; Mersana; Oncology Venture; Roche; Sotio; Takeda; Zai Lab

Consulting or Advisory Role - AstraZeneca; BioCad; Cerulean Pharma; Genmab; GlaxoSmithKline; Karyopharm Therapeutics; Pfizer; Sotio

Research Funding - Apexigen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Tesaro (Inst); Ultimovacs (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro

Other Relationship - European Network of Gynaecological Oncologic Trials; European Society for Gynaecological Oncology; Gynecological Cancer InterGroup

Robert L.  Coleman

Employment - US Oncology

Leadership - Onxeo

Stock and Other Ownership Interests  - McKesson

Consulting or Advisory Role - Abbvie; Agenus; Alkermes; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; GOG Foundation; Gradalis; Immunogen; Karyopharm Therapeutics; Merck; Merck; Novocure; OncoMed; OncXerna Therapeutics

Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); Immunogen (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (I)

Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group

Jose Alejandro  Perez-Fidalgo

Consulting or Advisory Role - Ability Pharma; Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Roche; Tesaro

Speakers' Bureau - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; Ipsen; Novartis; Pfizer; PharmaMar; Roche; Seagen

Research Funding - AstraZeneca Spain (Inst); GlaxoSmithKline (Inst); Pharmamar (Inst)

Patents, Royalties, Other Intellectual Property - Pending patent

Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer; Roche

(OPTIONAL) Uncompensated Relationships - AstraZeneca Spain; Novartis

Bradley J.  Monk

Leadership - US Oncology

Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics

Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics

Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK

Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)

Giorgio  Valabrega

Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; MSD

Consulting or Advisory Role - Eisai; GlaxoSmithKline

Travel, Accommodations, Expenses - MSD

Brian M.  Slomovitz

Consulting or Advisory Role - Agenus; AstraZeneca; Eisai; EQRx; Genentech; GlaxoSmithKline; GOG Foundation; Incyte; Lilly; Merck; Myriad Genetics; Nuvation Bio; Onconova Therapeutics; Onconova Therapeutics; Regeneron

Toon  Van Gorp

Consulting or Advisory Role - AstraZeneca (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst); Seagen (Inst)

Research Funding - Amgen (Inst); AstraZeneca (Inst); Roche (Inst)

Travel, Accommodations, Expenses - AstraZeneca (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)

Kathleen N.  Moore

Leadership - GOG Partners; NRG Oncology (Inst)

Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice

Consulting or Advisory Role - AADi; Alkermes (Inst); AstraZeneca; Blueprint Medicines (Inst); Caris Life Sciences; Clovis Oncology; Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); Hengrui Pharmaceutical; I-Mab (Inst); Immunogen; InxMed (Inst); Iovance Biotherapeutics; Merck; Mereo BioPharma; Mersana (Inst); Myriad Genetics; Novartis; Novartis/Pfizer; Onconova Therapeutics; OncXerna Therapeutics; VBL Therapeutics; Verastem/Pharmacyclics

Research Funding - Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)

Patents, Royalties, Other Intellectual Property - UpToDate

Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline

Other Relationship - GOG Partners (Inst)

Jalid  Sehouli

Honoraria - AstraZeneca; Bayer; Clovis Oncology; Eisai; GlaxoSmithKline; Johnson & Johnson; MSD Oncology; Olympus Medical Systems; Pfizer; PharmaMar; Tesaro; Teva

Consulting or Advisory Role - Alkermes; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Ingress Health; Johnson & Johnson; Lilly; Merck; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Riemser; Roche; Sobi; Tesaro

Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Tesaro (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG; Tesaro; Tesaro

David  Cibula

No Relationships to Disclose

Tally  Levy

No Relationships to Disclose

Gerasimos  Aravantinos

No Relationships to Disclose

Kai  Li

Employment - Karyopharm Therapeutics

Pratheek  Kalyanapu

Employment - Karyopharm Therapeutics

Vicky  Makker

Consulting or Advisory Role - ArQule; Clovis Oncology; DualityBio; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; ITeos Therapeutics; Kartos Therapeutics; Karyopharm Therapeutics; Lilly; Merck; Novartis; Takeda

Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); DualityBio (Inst); Eisai (Inst); Faeth Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - Eisai; Karyopharm Therapeutics; Merck

Other Relationship - IBM